Association between CETP gene polymorphism, insulin resistance and risk of diabetes mellitus in patients with vascular disease

Atherosclerosis

Volumn 242, Issue 2, 2015, Pages 605-610

  Koopal, Charlotte ^a   van der Graaf, Yolanda ^a   Asselbergs, Folkert W ^a,b,c   Westerink, Jan ^a   Visseren, Frank L J ^a   van Petersen, R ^b   van Dinther, B G F ^b   Doevendans, P A ^b   Algra, A ^b   van der Graaf, Y ^b   Grobbee, D E ^b   Rutten, G E H M ^b   Kappelle, L J ^b   Leiner, T ^b   Moll, F L ^b   Visseren, F L J ^b  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b ROYAL NETHERLANDS ACADEMY OF ARTS AND SCIENCES   (Netherlands)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Cardiovascular disease; Cholesteryl ester transfer protein (CETP); Diabetes mellitus type 2; Insulin resistance; Single nucleotide polymorphism (SNP)

Indexed keywords

CHOLESTEROL ESTER TRANSFER PROTEIN; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; CETP PROTEIN, HUMAN; TRIACYLGLYCEROL;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; FOLLOW UP; GENETIC ASSOCIATION; GENETIC VARIABILITY; HETEROZYGOTE; HOMOZYGOTE; HUMAN; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK; VASCULAR DISEASE; WILD TYPE; AGED; BLOOD; COMPLICATION; DIABETES MELLITUS; GENETICS; GENOTYPE; METABOLISM; MIDDLE AGED; QUESTIONNAIRE; RECURRENT DISEASE; REGRESSION ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM;

AGED; CARDIOVASCULAR DISEASES; CHOLESTEROL ESTER TRANSFER PROTEINS; DIABETES COMPLICATIONS; DIABETES MELLITUS; FEMALE; GENOTYPE; HETEROZYGOTE; HUMANS; INSULIN RESISTANCE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES; RECURRENCE; REGRESSION ANALYSIS; SURVEYS AND QUESTIONNAIRES; TRIGLYCERIDES; VASCULAR DISEASES;

EID: 84940403935     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2015.08.015     Document Type: Article

References (37)

1. Gatti A., Maranghi M., Bacci S., et al. Poor glycemic control is an independent risk factor for low HDL cholesterol in patients with type 2 diabetes. Diabetes Care 2009, 32(8):1550-1552.
2. Barter P.J., Rye K.A., Tardif J.C., et al. Effect of torcetrapib on glucose, insulin, and hemoglobin A1c in subjects in the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial. Circulation 2011, 124(5):555-562.
3. Inazu A., Brown M.L., Hesler C.B., et al. Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation. N. Engl. J. Med. 1990, 323(18):1234-1238.
4. Ridker P.M., Pare G., Parker A.N., et al. Polymorphism in the CETP gene region, HDL cholesterol, and risk of future myocardial infarction: genomewide analysis among 18 245 initially healthy women from the Women's Genome Health Study. Circ. Cardiovasc. Genet. 2009, 2(1):26-33.
5. Johannsen T.H., Frikke-Schmidt R., Schou J., et al. Genetic inhibition of CETP, ischemic vascular disease and mortality, and possible adverse effects. J. Am. Coll. Cardiol. 2012, 60(20):2041-2048.
6. Lopez-Rios L., Perez-Jimenez P., Martinez-Quintana E., et al. Association of Taq 1B CETP polymorphism with insulin and HOMA levels in the population of the Canary Islands. Nutr. Metab. Cardiovasc. Dis. 2011, 21(1):18-24.
7. Zhong S., Sharp D.S., Grove J.S., et al. Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels. J. Clin. Invest. 1996, 97(12):2917-2923.
8. Lopez-Rios L., Novoa F.J., Chirino R., et al. Interaction between cholesteryl ester transfer protein and hepatic lipase encoding genes and the risk of type 2 diabetes: results from the Telde study. PLoS One 2011, 6(11):e27208.
9. Papp A.C., Pinsonneault J.K., Wang D., et al. Cholesteryl Ester Transfer Protein (CETP) polymorphisms affect mRNA splicing, HDL levels, and sex-dependent cardiovascular risk. PLoS One 2012, 7(3):e31930.
10. Teslovich T.M., Musunuru K., Smith A.V., et al. Biological, clinical and population relevance of 95 loci for blood lipids. Nature 2010, 466(7307):707-713.
11. Chasman D.I., Pare G., Zee R.Y., et al. Genetic loci associated with plasma concentration of low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, apolipoprotein A1, and Apolipoprotein B among 6382 white women in genome-wide analysis with replication. Circ. Cardiovasc. Genet. 2008, 1(1):21-30.
12. Radovica I., Fridmanis D., Vaivade I., et al. The association of common SNPs and haplotypes in CETP gene with HDL cholesterol levels in Latvian population. PLoS One 2013, 8(5):e64191.
13. Simons P.C., Algra A., van de Laak M.F., et al. Second manifestations of ARTerial disease (SMART) study: rationale and design. Eur. J. Epidemiol. 1999, 15(9):773-781.
14. Grundy S.M., Cleeman J.I., Daniels S.R., et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and blood Institute Scientific Statement. Circulation 2005, 112(17):2735-2752.
15. Friedewald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin. Chem. 1972, 18(6):499-502.
16. Katz A., Nambi S.S., Mather K., et al. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J. Clin. Endocrinol. Metab. 2000, 85(7):2402-2410.
17. Simental-Mendia L.E., Rodriguez-Moran M., Guerrero-Romero F. The product of fasting glucose and triglycerides as surrogate for identifying insulin resistance in apparently healthy subjects. Metab. Syndr. Relat. Disord. 2008, 6(4):299-304.
18. McAuley K.A., Williams S.M., Mann J.I., et al. Diagnosing insulin resistance in the general population. Diabetes Care 2001, 24(3):460-464.
19. Matthews D.R., Hosker J.P., Rudenski A.S., et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28(7):412-419.
20. Wallace T.M., Levy J.C., Matthews D.R. Use and abuse of HOMA modeling. Diabetes Care 2004, 27(6):1487-1495.
21. Nova E., Baccan G.C., Veses A., et al. Potential health benefits of moderate alcohol consumption: current perspectives in research. Proc. Nutr. Soc. 2012, 71(2):307-315.
22. Tavintharan S., Lim S.C., Sum C.F. Patients with low levels of high-density lipoprotein cholesterol: to treat or not to treat?. Singap. Med. J. 2005, 46(10):519-528.
23. Donders A.R., van der Heijden G.J., Stijnen T., et al. Review: a gentle introduction to imputation of missing values. J. Clin. Epidemiol. 2006, 59(10):1087-1091.
24. Morris A.P., Voight B.F., Teslovich T.M., et al. Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetes. Nat. Genet. 2012, 44(9):981-990.
25. Drew B.G., Rye K.A., Duffy S.J., et al. The emerging role of HDL in glucose metabolism. Nat. Rev. Endocrinol. 2012, 8(4):237-245.
26. Brunham L.R., Kruit J.K., Pape T.D., et al. Beta-cell ABCA1 influences insulin secretion, glucose homeostasis and response to thiazolidinedione treatment. Nat. Med. 2007, 13(3):340-347.
27. Han R., Lai R., Ding Q., et al. Apolipoprotein A-I stimulates AMP-activated protein kinase and improves glucose metabolism. Diabetologia 2007, 50(9):1960-1968.
28. Drexel H., Aczel S., Marte T., et al. Is atherosclerosis in diabetes and impaired fasting glucose driven by elevated LDL cholesterol or by decreased HDL cholesterol?. Diabetes Care 2005, 28(1):101-107.
29. Buijsse B., Simmons R.K., Griffin S.J., et al. Risk assessment tools for identifying individuals at risk of developing type 2 diabetes. Epidemiol. Rev. 2011, 33:46-62.
30. Barter P., Gotto A.M., LaRosa J.C., et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N. Engl. J. Med. 2007, 357(13):1301-1310.
31. Gordon D.J., Rifkind B.M. High-density lipoprotein-the clinical implications of recent studies. N. Engl. J. Med. 1989, 321(19):1311-1316.
32. Virani S.S., Lee V.V., Brautbar A., et al. Single nucleotide polymorphisms in cholesteryl ester transfer protein gene and recurrent coronary heart disease or mortality in patients with established atherosclerosis. Am. J. Cardiol. 2013, 112(9):1287-1292.
33. Cao M., Zhou Z.W., Fang B.J., et al. Meta-analysis of cholesteryl ester transfer protein TaqIB polymorphism and risk of myocardial infarction. Medicine 2014, 93(26):e160.
34. Stitziel N.O., Won H.H., Morrison A.C., et al. Inactivating mutations in NPC1L1 and protection from coronary heart disease. N. Engl. J. Med. 2014, 371(22):2072-2082.
35. Plenge R.M., Scolnick E.M., Altshuler D. Validating therapeutic targets through human genetics. Nature reviews. Drug Discov. 2013, 12(8):581-594.
36. Li C., Zhang W., Zhou F., et al. Cholesteryl ester transfer protein inhibitors in the treatment of dyslipidemia: a systematic review and meta-analysis. PLoS One 2013, 8(10):e77049.
37. Sofat R., Hingorani A.D., Smeeth L., et al. Separating the mechanism-based and off-target actions of cholesteryl ester transfer protein inhibitors with CETP gene polymorphisms. Circulation 2010, 121(1):52-62.